- September 7, 2018
- Posted by: PharmaScroll
Xenon Pharmaceuticals reported the expansion of its ion channel product pipeline with XEN496 (active ingredient ezogabine), a Kv7 potassium channel modulator for the potential treatment of epilepsy. Based on feedback from the U.S. Food and Drug Administration (FDA), Xenon anticipates initiating a single, pivotal Phase 3 clinical trial in approximately mid-2019 examining XEN496’s efficacy as a precision medicine treatment of KCNQ2 epileptic encephalopathy (KCNQ2-EE) or EIEE7, which is a rare, severe, pediatric epilepsy caused by loss-of-function missense mutations in the KCNQ2 gene that encodes for the Kv7.2 channel. Published case reports where physicians have used ezogabine in infants and young children with KCNQ2-EE suggest that XEN496 may be efficacious in this often hard-to-treat patient population.
Ezogabine, also known as retigabine, is the only anti-epileptic drug previously approved by the FDA with a mechanism of action that potentiates Kv7-mediated potassium current. Ezogabine was originally approved by the FDA in June 2011 as an adjunctive treatment for adults with focal seizures with or without secondary generalization. GlaxoSmithKline (GSK) marketed ezogabine in various jurisdictions – as Potiga® in the U.S. and Trobalt™ in Europe – but withdrew the drug from the market worldwide in June 2017 citing commercial reasons.
Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “We have done an immense amount of diligence leading up to the addition of XEN496 to our novel and robust pipeline of ion-channel, anti-epileptic drugs. Based on feedback from key opinion leaders, advocacy groups, pre-existing literature, and promising data generated to date, we believe there is tremendous support for us to vigorously pursue the development and commercialization of XEN496 in order to reach the pediatric KCNQ2-EE patient population as rapidly as possible.”
Dr. Pimstone added, “We have already completed a number of critical steps to expedite our plans for XEN496. We have obtained a right of reference authorization from GSK so that the FDA can reference GSK’s regulatory filings to support Xenon’s own regulatory submissions, and we have also received orphan drug designation (ODD) from the FDA for XEN496 as a treatment of KCNQ2-EE. Additionally, our completed pre-IND interactions with the FDA, supported by the KCNQ2 Cure Alliance, key opinion leaders and parents of children with KCNQ2-EE, have been very positive and we believe they indicate support for a small, single, pivotal Phase 3 clinical trial in approximately 20 pediatric patients to support registration. Our ongoing work includes final pediatric formulation development in order to start the XEN496 Phase 3 clinical trial in approximately mid-2019.”
Jim Johnson, President, KCNQ2 Cure Alliance, stated, “To date, no drug has been specifically studied in clinical trials and approved for the treatment of KCNQ2 epileptic encephalopathy. There is a substantial unmet medical need for new therapies, especially those that target the underlying genetic cause of the seizures and cognitive decline observed in children with KCNQ2-EE. We are excited by Xenon’s announcement today outlining plans to develop XEN496 and their commitment to studying this drug in KCNQ2-EE. The KCNQ2 Cure Alliance is striving to identify and support the development of new and better treatments, and our hope is that XEN496 could represent a genetically targeted treatment that improves the lives of children living with this debilitating disease.”
As requested by Xenon, GSK authorized the FDA to refer to the information contained in GSK’s regulatory submissions for the purpose of the FDA’s review of Xenon’s regulatory filings. After consulting with clinical experts and patient advocacy groups, Xenon submitted a pre-IND briefing package to the FDA that outlined the proposed clinical development plans for XEN496. In response, the FDA indicated that it was acceptable to study XEN496 in infants and children up to 4 years old, and that a single pivotal trial in approximately 20 patients may be considered adequate in order to demonstrate XEN496’s efficacy in KCNQ2-EE. Recently, Xenon received ODD from the FDA for ezogabine as a treatment of KCNQ2-EE.
Xenon has formally established a steering committee made up of key opinion leaders in the epilepsy field to help guide the clinical development of XEN496. With input from this steering committee on the proposed trial design, dosing, and endpoints, the protocol development for the XEN496 Phase 3 clinical trial is currently underway. Xenon is working on a pediatric-specific formulation for XEN496 that may also address certain pigmentation issues associated with ezogabine, and it is anticipated that the Phase 3 clinical trial examining XEN496’s efficacy as a treatment of KCNQ2-EE will be initiated in approximately mid-2019. Additional details regarding the proposed clinical development of XEN496 are anticipated over the coming months.
There is strong human genetic validation and pharmacologic evidence, including published case studies that support the use of XEN496 as a potential treatment for KCNQ2-EE. The KCNQ2 gene encodes for the Kv7.2 voltage-gated potassium channel. Loss-of-function missense mutations in KCNQ2 can cause KCNQ2-EE, which is characterized in general, by multiple, daily, treatment-resistant seizures often presenting within the first week of life. XEN496 may have a greater potential to improve long term outcomes in KCNQ2-EE, as ezogabine enhances transmembrane potassium currents mediated by the Kv7.2/7.3 channels, thus potentially reversing the underlying genetic abnormality of KCNQ2-EE. By activating Kv7.2/7.3 channels, it is expected that XEN496 should stabilize the resting membrane potential and reduce brain excitability and may have the potential to improve brain function and cognitive development, in addition to decreasing seizures. In one previously published case report of 11 patients (Millichap 2016), ezogabine was associated with improvement in seizures and/or development in three of the four infants treated before six months of age, and two of the seven treated later. No serious adverse effects were observed in that study. Another study that included a review of medical records and structured interviews with families of eight children with KCNQ2-EE who had previously been prescribed ezogabine (Olson 2017), also suggested that ezogabine was effective and tolerable. Sustained improvement in seizure frequency was observed in five of the six patients with at least weekly seizures, along with improvements in development or cognition in all eight patients. The only adverse event reported was urinary retention in 3 patients and overall, ezogabine was well tolerated.
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Epilepsy indication, visit https://pharmascroll.com/news-category/epilepsy/
News Source: Xenon Pharma
Image Source: http://www.bctechnology.com/news/2016/9/21/Xenon-Pharmaceuticals-Announces-Closing-of-34.5-Million-Public-Offering.cfm